演題詳細

一般口演 / Oral Session

一般口演 105 (Oral Session 105) :免疫制御

print

日程
2013年10月13日(日)
時間
15:00 - 16:00
会場
第13会場 / Room No.13 (札幌市教育文化会館 3F 研修室301)
座長・司会
渋谷 彰 (Akira Shibuya):1
1:筑波大学医学医療系 免疫学
 
前へ戻る

Clinical study of WT1 peptide vaccination for pediatric leukemia after stem cell transplantation

演題番号 : OS-3-170

橋井 佳子 (Yoshiko Hashii):1、渡辺 新 (Arata Watanabe):2、坪井 昭博 (Akihiro Tuboi):3、尾路 祐介 (Yusuke Oji):4、保仙 直毅 (Naoki Hosen):5、宮村 能子 (Takako Miyamura):1、岡 芳弘 (Yoshihiro Oka):6、大薗 恵一 (Keiichi Ozono):1、杉山 治夫 (Haruo Sugiyama):7

1:Developmental Medicine Osaka University Graduate School of Medicine, Osaka, Japan、2:Nakadoori General Hospital, Akita, Japan、3:Cancer Immunother, Osaka Univ Grad Sch Med., Osaka, Japan、4:Cancer Stem Cell Biology, Osaka Univ Grad Sch Med., Osaka, Japan、5:Biomed Inform, Osaka Univ Grad Sch Med., Osaka, Japan、6:Resp Med, Allerg Rheum Disease, Osaka Univ Grad Sch Med., Osaka, Japan、7:Func Diag Sci, Osaka Univ Grad Sch Med., Osaka, Japan

 

Wilms tumor gene, WT1, is highly expressed in hematological malignancy. WT1-targeting strategies to enhance graft versus leukemia (GVL) response, therefore, may be useful to prevent recurrence after stem cell transplantation (SCT). In current study, we report the Phase I/II clinical study of WT1 peptide-based post SCT immunotherapy. Between from 2008 to 2012, a total of 7 patients with AML, 8 patients with ALL and one patient with NHL were enrolled. All of these patients were high risk of recurrence and had either relapsed after chemotherapy or prior SCT, or responded to chemotherapy with incomplete remission. HLA A2402 or A0201 -restricted 9 mer WT1 peptide emulsioned with Montanide ISA51. In 11 of 16 patients, disease has never relapsed for 5.1-55months (median 27mo). Although, of these 11 patients, seven patients had high WT1 mRNA level before vaccination in peripheral blood (PB) or bone marrow (BM), WT1 mRNA levels decreased to within normal level after vaccination. WT1-specific CTLs in PB were detected and increased after vaccination in all cases. Four patients recurred after transplant four or five, 7, 11 months later. One patient has been discontinued with vaccination due to pancreatitis induced by the steroid treatment of acute GVHD. Another adverse effect except local erythema and eruption at the injection site were not observed. We found that an increase in WT1-specific CTLs was associated with a decrease in WT1 mRNA, suggesting a WT1-driven GVL effect. Post-SCT vaccination of WT1 peptide should be a new tool to prevent the recurrence.

前へ戻る